RxDoctor Payments Data

Carletta Collins, MD

Hematology & Oncology · Powell, WYNPI 1740337617

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (58.8%), gifts and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Tosoh Bioscience, Inc. at 39.6% of the total. Reporting peaked in 2019 at $1,203 and has fallen 97.8% since, to $26 in 2025.

$1,361in general payments, 2019–2025

Across 58 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$539
  • Pfizer$170
  • Novartis$137
  • Eisai Inc.$99
  • Amgen$65
  • Daiichi Sankyo Inc.$64
  • plus $288 from 12 others

What the payments were for

  • Food & beverage$80059%
  • Education$222%
  • Gifts$53940%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology & oncology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$16,309
Medicare patients
71
Services billed
123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate16$390,936
XtandiEnzalutamide22$319,070
VerzenioAbemaciclib12$269,548
VenclextaVenetoclax11$80,911
Imatinib Mesylate12$6,214
Enoxaparin Sodium20$5,643
Letrozole78$1,528
Hydroxyurea26$977
Fluconazole20$650
Ondansetron OdtOndansetron26$502
Levothyroxine Sodium62$433
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$406
Anastrozole24$369
Warfarin Sodium37$239
Acyclovir28$237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio, Olanzapine$13$269,63623 claims
AbbVieVenclexta$42$80,91111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other hematology & oncology in Powell

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →